Literature DB >> 21409487

Financial and clinical implications of low-energy CT combined with 99m Technetium-sestamibi SPECT for primary hyperparathyroidism.

Giacomo Pata1, Claudio Casella, Gian Carlo Magri, Silvia Lucchini, Maria Beatrice Panarotto, Nicola Crea, Raffaele Giubbini, Bruno Salerni.   

Abstract

BACKGROUND: (99m)Technetium-sestamibi hybrid SPECT/CT has been favored over conventional SPECT in preoperative evaluation of primary hyperparathyroidism (PHPT) patients. However, the financial implications of CT-image acquisition have never before been published. This prompted us to perform a cost analysis of the aforementioned nuclear procedures.
METHODS: A total of 55 PHPT patients operated on between 2004 and 2009 were studied. Overall, 27 patients underwent SPECT and 28 SPECT/CT. Localization results, as well as diagnostic and clinical cost variations between SPECT and SPECT/CT patients, were compared.
RESULTS: SPECT/CT revealed higher sensitivity than SPECT (96.7 vs 79.3%; P = .011), as well as higher specificity (96.4 vs 82.4%; P = .037) and positive predictive value (PPV) (96.7 vs 83%; P = .038) for correctly identifying the neck-side affected by PHPT. Likewise, SPECT/CT disclosed higher sensitivity (86.7 vs 61.1%; P < .0001), specificity (97.4 vs 90%; P = .022), and PPV (86.7 vs 65.7%; P = .0001) for correct neck-quadrant identification. The mean operative time decreased from 62 min following SPECT to 36 min following SPECT/CT (P < .0001), yielding a mean surgical expense saving of 109.9 <euro>/patient (updated at 2009/2010 billing database). SPECT/CT actually ensures a mean expenditure reduction of 98.7 <euro>/patient (95% CI: 47.96 <euro>-149.42 <euro>), diagnostic costs variation amounting to 11.2 <euro>/procedure.
CONCLUSIONS: SPECT/CT ensures better focus for the surgical exploration, shortens surgical times, and eventually cuts costs when used for localization of parathyroid adenomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21409487     DOI: 10.1245/s10434-011-1641-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

2.  Correlation between biochemical features and outcomes of preoperative imaging (SPECT-CT and Ultrasound) in primary hyperparathyroidism.

Authors:  H Anderson; K H Lim; D Simpson; S Gull; R Oprean; F Lee; C Kakos; I T Cvasciuc
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

3.  The EANM practice guidelines for parathyroid imaging.

Authors:  Petra Petranović Ovčariček; Luca Giovanella; Ignasi Carrió Gasset; Elif Hindié; Martin W Huellner; Markus Luster; Arnoldo Piccardo; Theresia Weber; Jean-Noël Talbot; Frederik Anton Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-10       Impact factor: 9.236

4.  Comparison of five parathyroid scintigraphic protocols.

Authors:  Virpi Tunninen; Pekka Varjo; Jukka Schildt; Aapo Ahonen; Tomi Kauppinen; Irina Lisinen; Anu Holm; Hannu Eskola; Marko Seppänen
Journal:  Int J Mol Imaging       Date:  2013-01-21

Review 5.  Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence.

Authors:  Ora Israel; O Pellet; L Biassoni; D De Palma; E Estrada-Lobato; G Gnanasegaran; T Kuwert; C la Fougère; G Mariani; S Massalha; D Paez; F Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-04       Impact factor: 9.236

6.  99mTc-MIBI single photon emission computed tomography/computed tomography for the incidental detection of rare parathyroid carcinoma.

Authors:  Zejun Chen; Jingjing Fu; Qing Shao; Bin Zhou; Feng Wang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.